Ugur Sahin Sells 36,000 Shares of BioNTech (NASDAQ:BNTX) Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 36,000 shares of BioNTech stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $97.78, for a total value of $3,520,080.00. Following the sale, the chief executive officer directly owned 708,709 shares in the company, valued at $69,297,566.02. This trade represents a 4.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Trading Down 1.8%

BioNTech stock opened at $96.40 on Friday. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The firm’s 50 day moving average price is $97.00 and its 200-day moving average price is $95.37. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The stock has a market cap of $24.38 billion, a P/E ratio of -12.31 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech’s revenue was down 59.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.60) EPS. On average, equities analysts predict that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BNTX. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. UBS Group upgraded BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the company from $117.00 to $135.00 in a report on Wednesday, May 27th. Morgan Stanley reduced their price objective on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. Finally, BMO Capital Markets cut BioNTech from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $128.00 to $105.00 in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

Institutional Trading of BioNTech

Large investors have recently made changes to their positions in the business. Royal Bank of Canada lifted its holdings in shares of BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after acquiring an additional 3,514 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in BioNTech during the first quarter valued at approximately $167,000. Russell Investments Group Ltd. raised its position in BioNTech by 368,800.0% during the second quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock valued at $1,178,000 after purchasing an additional 11,064 shares during the period. Natixis bought a new stake in shares of BioNTech in the 2nd quarter valued at approximately $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of BioNTech by 2.9% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock valued at $52,416,000 after purchasing an additional 13,788 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.